Nephros Debt to Equity Ratio 2010-2025 | NEPH
Current and historical debt to equity ratio values for Nephros (NEPH) over the last 10 years. The debt/equity ratio can be defined as a measure of a company's financial leverage calculated by dividing its long-term debt by stockholders' equity. Nephros debt/equity for the three months ending March 31, 2025 was 0.00.
| Nephros Debt/Equity Ratio Historical Data | |||
|---|---|---|---|
| Date | Long Term Debt | Shareholder's Equity | Debt to Equity Ratio |
| 2025-03-31 | $0.00B | $0.01B | 0.27 |
| 2024-12-31 | $0.00B | $0.01B | 0.31 |
| 2024-09-30 | $0.00B | $0.01B | 0.27 |
| 2024-06-30 | $0.00B | $0.01B | 0.40 |
| 2024-03-31 | $0.00B | $0.01B | 0.40 |
| 2023-12-31 | $0.00B | $0.01B | 0.42 |
| 2023-09-30 | $0.00B | $0.01B | 0.27 |
| 2023-06-30 | $0.00B | $0.01B | 0.20 |
| 2023-03-31 | $0.00B | $0.01B | 0.23 |
| 2022-12-31 | $0.00B | $0.01B | 0.24 |
| 2022-09-30 | $0.00B | $0.01B | 0.18 |
| 2022-06-30 | $0.00B | $0.01B | 0.20 |
| 2022-03-31 | $0.00B | $0.01B | 0.16 |
| 2021-12-31 | $0.00B | $0.02B | 0.20 |
| 2021-09-30 | $0.00B | $0.02B | 0.16 |
| 2021-06-30 | $0.00B | $0.02B | 0.20 |
| 2021-03-31 | $0.00B | $0.02B | 0.15 |
| 2020-12-31 | $0.00B | $0.02B | 0.19 |
| 2020-09-30 | $0.00B | $0.01B | 0.33 |
| 2020-06-30 | $0.00B | $0.01B | 0.36 |
| 2020-03-31 | $0.01B | $0.01B | 0.34 |
| 2019-12-31 | $0.00B | $0.01B | 0.51 |
| 2019-09-30 | $0.01B | $0.01B | 0.72 |
| 2019-06-30 | $0.01B | $0.01B | 0.77 |
| 2019-03-31 | $0.01B | $0.01B | 0.81 |
| 2018-12-31 | $0.00B | $0.01B | 0.55 |
| 2018-09-30 | $0.00B | $0.01B | 0.33 |
| 2018-06-30 | $0.00B | $0.00B | 0.52 |
| 2018-03-31 | $0.00B | $0.00B | 1.44 |
| 2017-12-31 | $0.00B | $0.00B | 1.56 |
| 2017-09-30 | $0.00B | $0.00B | 9.66 |
| 2017-06-30 | $0.00B | $0.00B | 2.63 |
| 2017-03-31 | $0.00B | $0.00B | 1.39 |
| 2016-12-31 | $0.00B | $0.00B | 3.02 |
| 2016-09-30 | $0.00B | $0.00B | 1.47 |
| 2016-06-30 | $0.00B | $0.00B | 1.39 |
| 2016-03-31 | $0.00B | $0.00B | 0.72 |
| 2015-12-31 | $0.00B | $0.00B | 0.49 |
| 2015-09-30 | $0.00B | $0.00B | 0.54 |
| 2015-06-30 | $0.01B | $-0.01B | -1.57 |
| 2015-03-31 | $0.01B | $-0.01B | -1.49 |
| 2014-12-31 | $0.01B | $-0.01B | -1.59 |
| 2014-09-30 | $0.00B | $0.00B | -9.04 |
| 2014-06-30 | $0.00B | $0.00B | 9.89 |
| 2014-03-31 | $0.00B | $0.00B | 2.99 |
| 2013-12-31 | $0.01B | $0.00B | -1.78 |
| 2013-09-30 | $0.00B | $0.00B | 4.94 |
| 2013-06-30 | $0.00B | $0.00B | 2.43 |
| 2013-03-31 | $0.00B | $0.00B | -2.61 |
| 2012-12-31 | $0.00B | $0.00B | -6.93 |
| 2012-09-30 | $0.00B | $0.00B | 11.25 |
| 2012-06-30 | $0.00B | $0.00B | 3.85 |
| 2012-03-31 | $0.00B | $0.00B | 2.48 |
| 2011-12-31 | $0.00B | $0.00B | 1.81 |
| 2011-09-30 | $0.00B | $0.00B | 0.56 |
| 2011-06-30 | $0.00B | $0.00B | 0.25 |
| 2011-03-31 | $0.00B | $0.00B | 0.31 |
| 2010-12-31 | $0.00B | $0.00B | 11.15 |
| 2010-09-30 | $0.00B | $0.00B | 1.11 |
| 2010-06-30 | $0.00B | $0.00B | 0.80 |
| 2010-03-31 | $0.00B | $0.00B | 0.62 |
| 2009-12-31 | $0.00B | $0.00B | 0.35 |
| 2009-09-30 | $0.00B | $0.00B | 0.00 |
| 2009-06-30 | $0.00B | $0.00B | 0.00 |
| 2009-03-31 | $0.00B | $0.00B | 0.80 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Products Manufacturing | $0.023B | $0.014B |
| Nephros develops advanced End Stage Renal Disease, or ESRD, therapy technology and products that would address both patient treatment needs and the clinical and financial needs of the treatment provider. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Abbott Laboratories (ABT) | United States | $235.835B | 28.36 |
| Boston Scientific (BSX) | United States | $157.798B | 39.50 |
| Stryker (SYK) | United States | $150.649B | 31.50 |
| EssilorLuxottica (ESLOY) | France | $134.205B | 0.00 |
| Medtronic (MDT) | Ireland | $111.543B | 16.29 |
| Lonza Group Ag (LZAGY) | Switzerland | $49.908B | 0.00 |
| Haleon (HLN) | United Kingdom | $49.033B | 27.90 |
| ResMed (RMD) | United States | $37.148B | 27.90 |
| GE HealthCare Technologies (GEHC) | United States | $33.471B | 15.89 |
| Agilent Technologies (A) | United States | $32.342B | 21.36 |
| Terumo (TRUMY) | Japan | $27.583B | 35.83 |
| Insulet (PODD) | United States | $22.931B | 90.01 |
| Koninklijke Philips (PHG) | Netherlands | $22.436B | 16.13 |
| Zimmer Biomet Holdings (ZBH) | United States | $18.948B | 12.17 |
| Baxter (BAX) | United States | $16.150B | 12.06 |
| Smith & Nephew SNATS (SNN) | United Kingdom | $12.745B | 0.00 |
| Sunny Optical Technology (SNPTF) | China | $9.032B | 0.00 |
| Demant (WILYY) | Denmark | $8.231B | 0.00 |
| Bio-Rad Laboratories (BIO) | United States | $6.767B | 23.55 |
| Lantheus Holdings (LNTH) | United States | $5.414B | 13.66 |
| Prestige Consumer Healthcare (PBH) | United States | $4.395B | 19.63 |
| Perrigo (PRGO) | Ireland | $3.739B | 9.48 |
| Haemonetics (HAE) | United States | $3.484B | 15.18 |
| Shandong Weigao Medical Polymer (SHWGF) | China | $3.459B | 0.00 |
| ICU Medical (ICUI) | United States | $3.396B | 25.05 |
| Envista Holdings (NVST) | United States | $3.000B | 24.93 |
| QuidelOrtho (QDEL) | United States | $2.203B | 15.15 |
| GN Store Nord (GNNDY) | Denmark | $2.097B | 17.37 |
| LeMaitre Vascular (LMAT) | United States | $1.942B | 43.41 |
| AtriCure (ATRC) | United States | $1.604B | 0.00 |
| Neogen (NEOG) | United States | $1.389B | 17.78 |
| Kestra Medical Technologies (KMTS) | United States | $1.245B | 0.00 |
| AdaptHealth (AHCO) | United States | $1.213B | 12.31 |
| Green Thumb Industries (GTBIF) | United States | $1.175B | 26.43 |
| BioLife Solutions (BLFS) | United States | $1.090B | 0.00 |
| InMode (INMD) | Israel | $1.011B | 9.25 |
| Phibro Animal Health (PAHC) | United States | $0.978B | 12.50 |
| CeriBell (CBLL) | United States | $0.644B | 0.00 |
| Evolus (EOLS) | United States | $0.638B | 0.00 |
| Curaleaf Holdings (CURLF) | Canada | $0.566B | 0.00 |
| Maravai LifeSciences Holdings (MRVI) | United States | $0.553B | 0.00 |
| Owens & Minor (OMI) | United States | $0.548B | 4.54 |
| Valneva SE (VALN) | France | $0.530B | 0.00 |
| Capricor Therapeutics (CAPR) | United States | $0.474B | 0.00 |
| Tilray Brands (TLRY) | Canada | $0.456B | 0.00 |
| Surmodics (SRDX) | United States | $0.422B | 0.00 |
| Cresco Labs (CRLBF) | United States | $0.349B | 0.00 |
| SNDL (SNDL) | Canada | $0.342B | 0.00 |
| VAREX IMAGING (VREX) | United States | $0.330B | 12.14 |
| Canopy Growth (CGC) | Canada | $0.302B | 0.00 |
| SEMPERIT AG HLD (SEIGY) | Austria | $0.300B | 0.00 |
| Aurora Cannabis (ACB) | Canada | $0.282B | 50.20 |
| Sanara MedTech (SMTI) | United States | $0.277B | 0.00 |
| Viemed Healthcare (VMD) | United States | $0.267B | 22.50 |
| Sanuwave Health (SNWV) | United States | $0.253B | 0.00 |
| Cerus (CERS) | United States | $0.252B | 0.00 |
| Verano Holdings (VRNOF) | United States | $0.250B | 0.00 |
| ZimVie (ZIMV) | United States | $0.244B | 11.08 |
| Biote (BTMD) | United States | $0.222B | 6.25 |
| Brainsway (BWAY) | Israel | $0.201B | 53.25 |
| OraSure Technologies (OSUR) | United States | $0.197B | 0.00 |
| Omeros (OMER) | United States | $0.195B | 0.00 |
| High Tide (HITI) | Canada | $0.190B | 0.00 |
| Quanterix (QTRX) | United States | $0.189B | 0.00 |
| Utah Medical Products (UTMD) | United States | $0.177B | 14.41 |
| Organigram Global (OGI) | Canada | $0.175B | 0.00 |
| TriSalus Life Sciences (TLSI) | United States | $0.167B | 0.00 |
| Exagen (XGN) | United States | $0.135B | 0.00 |
| FitLife Brands (FTLF) | United States | $0.130B | 15.94 |
| Jin Medical (ZJYL) | China | $0.126B | 0.00 |
| TerrAscend (TSNDF) | Canada | $0.116B | 0.00 |
| Agape ATP (ATPC) | $0.102B | 0.00 | |
| MacroGenics (MGNX) | United States | $0.100B | 0.00 |
| Oramed Pharmaceuticals (ORMP) | United States | $0.087B | 0.00 |
| Fonar (FONR) | United States | $0.084B | 10.81 |
| Veru (VERU) | United States | $0.076B | 0.00 |
| Jushi Holdings (JUSHF) | United States | $0.073B | 0.00 |
| InterCure (INCR) | Israel | $0.072B | 0.00 |
| Zynex (ZYXI) | United States | $0.071B | 0.00 |
| Quipt Home Medical (QIPT) | United States | $0.060B | 0.00 |
| United Health Products (UEEC) | United States | $0.058B | 0.00 |
| Apyx Medical (APYX) | United States | $0.056B | 0.00 |
| Cytosorbents (CTSO) | United States | $0.053B | 0.00 |
| ImmuCell (ICCC) | United States | $0.050B | 0.00 |
| Modular Medical (MODD) | United States | $0.040B | 0.00 |
| United-Guardian (UG) | United States | $0.040B | 13.69 |
| Rockwell Medical (RMTI) | United States | $0.036B | 0.00 |
| Safety Shot (SHOT) | United States | $0.030B | 0.00 |
| Allurion Technologies (ALUR) | United States | $0.023B | 0.00 |
| INLIF (INLF) | $0.018B | 0.00 | |
| Flora Growth (FLGC) | United States | $0.015B | 0.00 |
| Trinity Biotech (TRIB) | Ireland | $0.015B | 0.00 |
| Cellectar Biosciences (CLRB) | United States | $0.012B | 0.00 |
| Meihua Medical Technologies (MHUA) | China | $0.009B | 0.00 |
| Innovative Eyewear (LUCY) | United States | $0.008B | 0.00 |
| Senestech (SNES) | United States | $0.005B | 0.00 |
| GlucoTrack (GCTK) | United States | $0.004B | 0.00 |
| IM Cannabis (IMCC) | Canada | $0.003B | 0.00 |
| Akanda (AKAN) | Canada | $0.002B | 0.00 |
| Sharps Technology (STSS) | United States | $0.000B | 0.00 |
| InVivo Therapeutics Holdings (NVIVQ) | United States | $0.000B | 0.00 |
| Acuren (TIC) | United States | $0.000B | 0.00 |